View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/SAMHSA RIN: 0930-AA38 Publication ID: Spring 2022 
Title: Treatment of Opioid Use Disorder With Buprenorphine Utilizing Telehealth 
Abstract:

In the face of an escalating overdose crisis and an increasing need to reach remote and underserved communities, extending the buprenorphine telehealth flexibility is of paramount importance. To permanently continue this flexibility among OTPs after the COVID-19 public health emergency ends, SAMHSA proposes to revise OTP regulations under 42 CFR part 8.

 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: Yes  Unfunded Mandates: No 
CFR Citation: 42 CFR 8.11 (h)   
Legal Authority: The Controlled Substances Act, as amended by the Ryan Haight Act (21 U.S.C. sec. 802(54)(G))   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  09/00/2022 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: Yes 
RIN Data Printed in the FR: No 
Agency Contact:
Dr. Neeraj Gandotra
Chief Medical Officer
Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
5600 Fishers Lane, 18E67,
Rockville, MD 20857
Phone:202 823-1816
Email: neeraj.gandotra@samhsa.hhs.gov